EMA-EUnetHTA Joint Work Plan for 2017-2020
This is the EMA-EUnetHTA Joint Work Plan for 2017-2020 EMA-EUnetHTA work plan 2017 - 2020 - for publication
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report
An analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report WP7 Activity 1 Report Template for deliverable 7.1 Annex 1_agency data Annex 2_case studies
Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)
This is the final project plan of the pharma JA on Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC). Project plan_PTJA03_Alectinib_final
1st Collaborative Assessment – Wearable cardioverter-defibrillator (WCD) therapy in primary and secondary prevention of sudden cardiac arrest in patients at risk
Sudden cardiac arrest (SCA) is the most common cause of death in patients with coronary artery disease. Mostly, ventricular tachycardia and ventricular fibrillation are the underlying aetiology of SCA, which is claimed to be successfully treated by a novel defibrillation